Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DCPH Hot Sheet
Join SI Premium – FREE
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($0.60), $0.03 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $36.35 million versus the consensus estimate of $35.67 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptiv (APTV) Tops Q3 EPS by 9c; offers guidance
- Enlight Renewable Energy Ltd (ENLT) Tops Q3 EPS by 11c; Offers Guidance
- SOPHiA GENETICS SA (SOPH) Misses Q3 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
